Drug intelligence / Profile preview

RG6351

Development stage: Phase 2
Lead developer: Roche
Modality: Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Ophthalmic

Overview

RG6351 (also known as RO7446603) is a novel multivalent Tie2 agonist developed by Roche for the treatment of diabetic macular edema (DME). The drug is engineered as a Fab-PEG-hexamer conjugate, featuring six antibody Fab fragments linked to a polyethylene glycol (PEG) core. This unique hexameric structure is designed to induce clustering and activation of the Tie2 receptor (TEK tyrosine kinase) on endothelial cells, effectively mimicking the vascular-stabilizing activity of the natural ligand Angiopoietin-1. By activating the Tie2 pathway, RG6351 aims to restore the blood-retinal barrier, reduce vascular permeability, and suppress inflammatory processes that contribute to vision loss in DME. It is currently being evaluated in Phase 2 clinical trials as an intravitreal injection.

Other names: Tie2-Fab-PEG-hexamer conjugateTie-2-Fab-PEG-hexamer conjugateTie 2-Fab-PEG-hexamer conjugate

Targets

TEK (Tie2)

Beyond the preview

Go deeper on RG6351.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG6351.

Explore the full profile